In this issue:
PMRT for patients with 1–3 lymph nodes
Biosimilar trastuzumab looks promising
Targeted exercise improves metabolic syndrome
Enzalutamide in advanced AR+ TNBC
Prosigna ROR score in ER+ disease
Adjuvant AIs, upfront or after tamoxifen, in endocrine-sensitive disease
Adding veliparib + carboplatin to standard AC-paclitaxel in TNBC
Trastuzumab + pertuzumab ± metronomic chemo for HER2+ disease
RDI and survival of ER+/PR+, HER2–, and TNBC patients
Comparing maintenance nab-paclitaxel schedules in metastatic disease
Please login below to download this issue (PDF)